Frankfurt
25.03.26 | 09:55
4,960 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | INVENTIVA: Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results | 427 | GlobeNewswire (Europe) | Daix (France), New York (United States), March 23, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 18.03. | Truist initiates Inventiva stock with buy on MASH therapy potential | 5 | Investing.com | ||
| 03.03. | Danaher, Moderna, Emyria: Drei Biotech-Aktien für die Beobachtungsliste im März 2026 | Small- & Micro Cap Investment | |||
| 26.02. | INVENTIVA: Inventiva to Participate in Four Upcoming March Investor Conferences | 396 | GlobeNewswire (Europe) | Daix (France), New York (United States), February 26, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 17.02. | Inventiva S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 17.02. | INVENTIVA: Inventiva reports preliminary 2025 fiscal year financial results | 542 | GlobeNewswire (Europe) | Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5 million in 2025Completed a U.S. registered public offering for gross proceeds... ► Artikel lesen | |
| 04.02. | INVENTIVA: Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | 330 | GlobeNewswire (Europe) | Daix (France), New York (United States), February 4, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 28.01. | H.C. Wainwright reiterates Buy rating on Inventiva stock at $24 price target | 4 | Investing.com | ||
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 26.01. | INVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux | 819 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), January 26, 2026 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 12.01. | Leerink Partners initiates coverage on Inventiva stock with Outperform rating | 12 | Investing.com | ||
| 07.01. | UBS startet Coverage für Inventiva mit Kaufempfehlung und 12-Dollar-Kursziel | 13 | Investing.com Deutsch | ||
| 07.01. | UBS assumes coverage on Inventiva stock with Buy rating, $12 target | 19 | Investing.com | ||
| 17.12.25 | INVENTIVA: Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference | 448 | GlobeNewswire (Europe) | Daix) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH")... ► Artikel lesen | |
| 28.11.25 | Inventiva S.A. - 6-K, Report of foreign issuer | 13 | SEC Filings | ||
| 28.11.25 | INVENTIVA: Results of the Votes of the Combined Shareholders' General Meeting of November 27, 2025 | 669 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 28, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 24.11.25 | INVENTIVA: Information relating to the stabilization activities carried out in the context of its recent offering | 418 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), November 24, 2025 - Publication of information relating to the stabilization activities carried out in the context of the recent public offering... ► Artikel lesen | |
| 24.11.25 | Inventiva S.A. reports nine-months results | 4 | Seeking Alpha | ||
| 21.11.25 | Inventiva S.A reports 9M results | 1 | Seeking Alpha | ||
| 21.11.25 | INVENTIVA: Inventiva reports 2025 Third Quarter Financial Information | 917 | GlobeNewswire (Europe) | Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the... ► Artikel lesen | |
| 18.11.25 | Inventiva stock price target lowered to $11 at Guggenheim on financing | 9 | Investing.com |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 10,645 | -2,11 % | EyePoint lawsuit accuses Ocular of 'malicious' defamation campaign in retina drug race | ||
| EDWARDS LIFESCIENCES | 70,37 | -0,24 % | Edwards Lifesciences Corp. Q4 Profit Falls | WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) announced earnings for fourth quarter that Drops, from last yearThe company's earnings totaled $91.2 million, or $0.16 per share. This... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,120 | -4,27 % | Organigram Global Inc: Organigram garners ISS support for Sanity transaction | ||
| ASSEMBLY BIOSCIENCES | 24,600 | +1,23 % | Assembly Biosciences: "Wir erwarten ein weiteres starkes Jahr" | Der Virologieforscher Assembly Biosciences blickt nach einem entscheidenden Jahr 2025 auf eine positive Zukunft. Im jüngsten Geschäftsbericht wird eine Ausweitung der Pipeline angedeutet. Es könnte... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,020 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness Announces the Grand Opening of Its Newest Location in Ottawa, Ontario | Toronto, Ontario--(Newsfile Corp. - March 20, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 140,00 | +2,23 % | Guggenheim raises Axsome stock price target on Alzheimer's drug outlook | ||
| COMPASS PATHWAYS | 4,540 | 0,00 % | 3 spannende Psychedelika-Aktien für 2026: Medizinische Innovation trifft auf Marktdynamik | ||
| ACHIEVE LIFE SCIENCES | 2,595 | 0,00 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| ALTIMMUNE | 2,847 | +0,57 % | Altimmune: Truist startet Coverage mit Kaufempfehlung dank Wirkstoff-Potenzial | ||
| JAZZ PHARMACEUTICALS | 166,00 | +3,88 % | Bioxyne Limited hebt Prognose an - Jazz Pharma mit Kaufempfehlung: Zwei Aktien für das Biotech-Comeback | ||
| DAIICHI SANKYO | 16,260 | +0,06 % | Daiichi Sankyo's cancer drug approved as second-line therapy in Japan | ||
| SELLAS LIFE SCIENCES | 4,345 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| XORTX THERAPEUTICS | 0,345 | 0,00 % | XORTX Therapeutics Inc.: XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting | CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| AYTU BIOPHARMA | 1,570 | -100,00 % | Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results | Total net revenue of $15.2 millionAdjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments$30.0 million cash balance at December 31, 2025Company launched EXXUA (gepirone) extended-release... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 22,200 | -1,77 % | Rigel Pharmaceuticals, Inc.: Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million
2025... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.